Needham analyst Mike Matson lowered the firm’s price target on Haemonetics (HAE) to $68 from $84 and keeps a Buy rating on the shares. The company’s Q1 topped estimates but it maintained prior guidance despite the beat, the analyst tells investors in a research note. The firm says the the stock is trading down 21% given deterioration in Haemonetics’ Interventional Technologies business.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics backs FY26 adjusted EPS view $4.70-$5.10, consensus $4.87
- Haemonetics reports Q1 EPS $1.10, consensus $1.02
- HAE Upcoming Earnings Report: What to Expect?
- Haemonetics Holds Successful Annual Shareholders Meeting
- Haemonetics Receives Buy Rating Amid Strategic Positioning and Positive Long-term Outlook